292 related articles for article (PubMed ID: 33408016)
1. Can we use hydroxychloroquine to treat COVID-19 now?
Chen J; Liu D; Yin L; Zhang L; Lu H
Int J Antimicrob Agents; 2021 Jan; 57(1):106173. PubMed ID: 33408016
[No Abstract] [Full Text] [Related]
2. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Goldman JD; Diaz G; Urba WJ
Int J Antimicrob Agents; 2021 Jan; 57(1):106174. PubMed ID: 33408020
[No Abstract] [Full Text] [Related]
3. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Saad MO
Int J Antimicrob Agents; 2021 Jan; 57(1):106171. PubMed ID: 33408024
[No Abstract] [Full Text] [Related]
4. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Dos Santos MR
Int J Antimicrob Agents; 2021 Jan; 57(1):106176. PubMed ID: 33408022
[No Abstract] [Full Text] [Related]
5. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Wambier CG
Int J Antimicrob Agents; 2021 Jan; 57(1):106175. PubMed ID: 33408021
[No Abstract] [Full Text] [Related]
6. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Nguyen TV
Int J Antimicrob Agents; 2021 Jan; 57(1):106169. PubMed ID: 33408026
[No Abstract] [Full Text] [Related]
7. Advanced statistical methods and designs for clinical trials for COVID-19.
Shan G; Wang W
Int J Antimicrob Agents; 2021 Jan; 57(1):106167. PubMed ID: 33408032
[No Abstract] [Full Text] [Related]
8. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
Gautret P; Honoré S; Lagier JC; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106236. PubMed ID: 33408025
[No Abstract] [Full Text] [Related]
9. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Parra-Lara LG; Martinez-Arboleda JJ; Isaza-Pierotti DF; Rosso F
Int J Antimicrob Agents; 2021 Jan; 57(1):106172. PubMed ID: 33408017
[No Abstract] [Full Text] [Related]
10. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.
De Schryver N; Serck N; Vinetti M; Gérard L
Int J Antimicrob Agents; 2021 Jan; 57(1):106254. PubMed ID: 33259917
[No Abstract] [Full Text] [Related]
11. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Million M; Roussel Y; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
[No Abstract] [Full Text] [Related]
12. Doxycycline as an Alternative to Azithromycin in Elderly Patients.
Malek AE; Granwehr BP
Int J Antimicrob Agents; 2021 Jan; 57(1):106168. PubMed ID: 33408018
[No Abstract] [Full Text] [Related]
13. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
[No Abstract] [Full Text] [Related]
14. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
[No Abstract] [Full Text] [Related]
15. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
[No Abstract] [Full Text] [Related]
16. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Gautret P; Hoang VT; Lagier JC; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106239. PubMed ID: 33408029
[No Abstract] [Full Text] [Related]
17. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798
[No Abstract] [Full Text] [Related]
18. Azithromycin, a questionable treatment for COVID-19.
Belfaqeeh O; Janapala RN; Patel J; Alhashmi A; Pourmand A
Int J Antimicrob Agents; 2021 Mar; 57(3):106280. PubMed ID: 33476733
[No Abstract] [Full Text] [Related]
19. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]